Ubs Group Ag Kempharm, Inc Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Kempharm, Inc stock. As of the latest transaction made, Ubs Group Ag holds 343,818 shares of KMPH stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

343,818

Previous 19,934 1624.78%

Holding current value

$1.7 Million

Previous $98,000 1632.65%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	N/A	323,884 Added 1624.78%	343,818 $1.7 Million
Q3 2024 Nov 14, 2024	BUY	N/A	7,002 Added 54.14%	19,934 $98,000
Q2 2024 Aug 13, 2024	SELL	N/A	-30,016 Reduced 69.89%	12,932 $63,000
Q1 2024 May 13, 2024	BUY	N/A	7,838 Added 22.32%	42,948 $212,000
Q4 2023 Feb 09, 2024	BUY	N/A	16,368 Added 87.33%	35,110 $173,000
Q3 2023 Nov 09, 2023	SELL	N/A	-1,350 Reduced 6.72%	18,742 $92,000
Q2 2023 Aug 11, 2023	BUY	$4.94 - $6.29 $78,807 - $100,344	15,953 Added 385.43%	20,092 $99,000
Q1 2023 May 12, 2023	SELL	$4.13 - $6.27 $11,737 - $17,819	-2,842 Reduced 40.71%	4,139 $22,000
Q4 2022 Feb 08, 2023	BUY	$4.12 - $5.62 $24,736 - $33,742	6,004 Added 614.53%	6,981 $32,000
Q3 2022 Nov 10, 2022	SELL	$4.5 - $6.85 $21,694 - $33,023	-4,821 Reduced 83.15%	977 $6,000
Q2 2022 Aug 10, 2022	BUY	$4.02 - $5.21 $23,307 - $30,207	5,798 New	5,798 $26,000
Q1 2022 May 16, 2022	SELL	$5.0 - $9.26 $52,495 - $97,220	-10,499 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.6 - $10.26 $79,792 - $107,719	10,499 New	10,499 $92,000
Q2 2021 Aug 13, 2021	SELL	$8.52 - $15.47 $113,171 - $205,488	-13,283 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$5.6 - $13.47 $74,384 - $178,922	13,283 New	13,283 $122,000

Others Institutions Holding KMPH

# of Institutions

115

Shares Held

30.2M

Call Options Held

284K

Put Options Held

24.1K

View Full List

About KEMPHARM, INC

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

More about KMPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account